Skip to main content

Table 2 Parameter estimates of the final population pharmacokinetic model of paracetamol in patients with falciparum malaria

From: Pharmacokinetic properties of intramuscular versus oral syrup paracetamol in Plasmodium falciparum malaria

Parameter Population estimatea
(%RSE)b
95 % CIb IIV (%CV)a
(%RSE)b
95 % CIb
FIM 1 fixed
FPO 0.844 (8.4) 0.682–0.951 287 (49.1) 76.5–1038
DURIM (h) 0.689 (6.2) 0.621–0.784
ka,PO (h−1) 4.15 (44.5) 1.95–9.73 232 (49.7) 39.9–574
CL (l/h) 10.7 (16.9) 7.35–14.7 81.8 (69.7) 24.4–164
VC (l) 45.5 (8.5) 36.7–51.5
Q (l/h) 10.3 (36.8) 4.80–20.1 77.4 (44.0) 21.1–105
VP (l) 11.3 (42.7) 5.01–29.0 428 (46.5) 112–2351
σ 0.376 (7.8) 0.316–0.436
  1. F IM bioavailability after intramuscular administration, F PO relative bioavailability after oral syrup administration, DUR IM duration of zero-order absorption after intramuscular administration, k a,PO absorption rate constant after oral syrup administration, CL apparent elimination clearance, V C apparent volume of distribution of the central compartment, Q inter-compartment clearance, V P apparent volume of distribution of the peripheral compartment, σ variance of the residual variability
  2. aPopulation mean values and inter-individual variability (IIV) estimated by NONMEM. The coefficient of variation (% CV) for IIV was calculated as \(100 \times \sqrt {\exp ({\text{estimate}}){ - }1}\)
  3. bThe relative standard error (%RSE) was calculated as \(100 \times \left( {\frac{\text{SD}}{{{\text{Mean}}\;{\text{value}}}}} \right)\) from the non-parametric bootstrap results (n = 1000). The 95 % confidence interval (95 % CI) is presented as the 2.5–97.5 percentiles of the bootstrap estimates